Glenmede Trust’s Aratana Therapeutics, Inc. PETX Stock Holding History

Glenmede Trust’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-370	Closed	-$1	–	3212
2019 Q2	$1	Hold	370	–	–	﹤0.01%	3027
2019 Q1	$1	Buy	370 +264	+249%	+$1.14K	﹤0.01%	3010
2018 Q4	$0	Buy	+106	New	+$647	﹤0.01%	3134
2016 Q4	–	Sell	-106	Closed	–	–	2692
2016 Q3	$0	Buy	+106	New	+$880	﹤0.01%	2725
2015 Q3	–	Sell	-1	Closed	–	–	2885
2015 Q2	$0	Hold	1	–	–	﹤0.01%	2820
2015 Q1	$0	Buy	+1	New	+$18	﹤0.01%	2595

Other funds holding PETX

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Glenmede Trust's PETX Position: Q3 2019 in Review

Glenmede Trust sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2019, closing a stake of 370 shares — an estimated $1 sold.

Glenmede Trust first reported a position in PETX in Q1 2015 and held it in 6 quarters. The position peaked at $1 in Q2 2019. 2 funds tracked by Wall St. Rank hold PETX as of Q3 2019.

Glenmede Trust reported no remaining Aratana Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
Glenmede Trust sold 370 Aratana Therapeutics, Inc. shares in Q3 2019, an estimated $1.
Glenmede Trust first reported a position in Aratana Therapeutics, Inc. in Q1 2015 and held it in 6 quarters.
Glenmede Trust's Aratana Therapeutics, Inc. position peaked at $1 in Q2 2019.
2 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2019.

Based on Glenmede Trust's 13F filing for Q3 2019, filed 14 Nov 2019.